David Kessler likely to retire from the FDA:
This article was originally published in Clinica
Executive Summary
After six years as commissioner of the US FDA, The Washington Times reports that David Kessler intends to join the exodus of top-level officials from President Clinton's administration. Dr Kessler has been assiduous in efforts to have nicotine classified as a drug and thus made subject to regulation. He has also led attempts to speed the agency's approvals processes for drugs and devices. Dr Kessler's spokesman told Clinica that the commissioner's departure was not imminent, but that Dr Kessler had accomplished all his long term goals for the agency.
You may also be interested in...
A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.